Mastic gum is a resinous secretion of the mastic tree (Pistacia lentiscus var. Chia), grown almost exclusively on the Greek island of Chios. It has been used medicinally in the Mediterranean region for over 2,500 years â for oral health, digestive complaints, and wound healing. It produces a characteristic pine-like aroma and is still chewed as a traditional remedy and food flavouring in Greece and the Middle East.
Mastic gum contains a complex mixture of triterpenic acids, polymers, and essential oil compounds. Laboratory work has identified several components with antibacterial activity against multiple organisms, including Helicobacter pylori â the gram-negative bacterium responsible for the majority of gastric ulcers and linked to gastric adenocarcinoma and MALT lymphoma.
H. pylori infection is very common globally â estimated to affect over 50% of the world's population, with lower but still significant rates in Ireland. Standard treatment is triple or quadruple antibiotic therapy (typically including a proton pump inhibitor, clarithromycin, and amoxicillin), which achieves eradication rates of 70â90% but is complicated by rising antibiotic resistance.
The starting point for mastic gum's reputation as an H. pylori remedy is a letter to The Lancet published in December 1998 by Huwez and colleagues. This letter reported that mastic gum at 1 mg/day for two weeks killed H. pylori in vitro in 12 of 12 strains tested, and that three of seven H. pylori-positive patients treated with mastic gum showed clearance of the infection. This short correspondence â not a peer-reviewed clinical trial â generated enormous attention and spawned a global mastic gum supplement market almost overnight.
The importance of context here cannot be overstated: a letter to the editor, based on preliminary in vitro data and seven patients, is the weakest possible form of clinical evidence. It is hypothesis-generating, not hypothesis-confirming. The letter was subsequently cited thousands of times in supplement marketing, typically without this crucial context.
The obvious next step after the Huwez letter was to conduct a properly powered, controlled clinical trial. Several followed, with surprisingly inconsistent results.
Bebb et al. (2003) â Helicobacter journal: A double-blind RCT comparing mastic gum (350 mg three times daily) vs placebo in 38 H. pylori-positive patients. After 4 weeks of treatment, H. pylori eradication rates were 3/19 (16%) in the mastic gum group vs 4/19 (21%) in the placebo group. No statistically significant benefit. This was the first rigorous negative trial for mastic gum in H. pylori eradication.
Loughlin et al. (2003) found that while mastic gum inhibited H. pylori growth in vitro, the minimum inhibitory concentrations (MICs) were variable and substantially higher than concentrations achievable with standard supplementation â suggesting the in vitro activity may not translate to clinical therapeutic levels in the stomach.
A 2010 study by Dabos et al. using higher-dose mastic gum (2.38 g/day for 14 days) found more promising eradication rates than lower-dose trials, suggesting a dose-dependent effect. Results improved when mastic gum was combined with PPI therapy â suggesting potential as an adjunct to, rather than replacement for, conventional H. pylori treatment.
| Claim | Evidence Level | Source |
|---|---|---|
| Kills H. pylori in vitro | Strong (in vitro) | Huwez 1998; multiple laboratory studies |
| Eradicates H. pylori as monotherapy at low dose | Not Supported | Bebb et al. 2003 RCT â no benefit vs placebo |
| Eradicates H. pylori at higher doses | Limited | Dabos et al. 2010 â promising but small, no placebo control |
| Useful adjunct to PPI therapy | Limited | Preliminary data; needs larger trials |
| Improves functional dyspepsia symptoms | Moderate | Dabos et al. 2004 â significant symptom improvement (n=148) |
While the H. pylori eradication data is disappointing for low-dose mastic gum, the evidence for symptom relief in functional dyspepsia is more credible. Dabos et al. (2004) conducted a double-blind RCT (n=148) comparing mastic gum 350 mg three times daily vs placebo for three months in patients with functional dyspepsia. The mastic gum group showed significantly greater improvement in symptoms including upper abdominal pain, stomach ache, and heartburn. This remains the best-evidenced clinical application for mastic gum â symptomatic relief of upper GI discomfort rather than bacterial eradication.
Mastic gum is typically sold in capsule form (pure resin powder) at 500 mgâ1,000 mg per capsule. Typical doses in Irish health shops are 1,000â3,000 mg/day for gastric or H. pylori support, taken on an empty stomach before meals. The dyspepsia RCT used 350 mg three times daily. For genuine H. pylori eradication intent, the limited evidence suggests higher doses (2 g+/day) are needed â and standard antibiotic triple therapy remains the evidence-based first-line treatment.
Mastic gum has a good safety profile based on its long history of food and medicinal use. No serious adverse events have been reported in clinical trials. The most commonly reported side effect is mild headache at higher doses. GI side effects are uncommon.
Mastic gum has mild antioxidant and anti-inflammatory properties. No significant drug interactions are documented, though it has not been extensively evaluated for pharmaceutical interactions.
Mastic gum's H. pylori story is a cautionary tale about how a single preliminary observation can build an entire supplement market. The in vitro activity is real; the clinical eradication evidence at commonly sold doses is not. For functional dyspepsia and general upper GI symptom support, mastic gum has more credible clinical evidence. If you have a confirmed H. pylori infection, antibiotic triple therapy remains the standard of care. Mastic gum may be a reasonable adjunct to discuss with your GP, but not a replacement.